Age: 12.0
Sex: F
Vaccine: HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no adverse effects; Administered after Temperature excursion; This spontaneous report was received from a physician referring to a 12-year-old female patient. Her historical vaccines included hepatitis B vaccine (manufacturer unknown) (28-MAY-2011, 02-AUG-2011 and 02-MAR-2012) (captured # 2307USA010128), rotavirus vaccine (+) live (+) oral (+) pentavalent (ROTATEQ) (02-AUG-2011, 30-SEP-2011, 02-DEC-2011), pneumococcal vaccine conj 13v (crm197) (PREVNAR 13) (02-AUG-2011, 30-SEP-2011, 02-DEC-2011 and 29-MAY-2012), diphtheria vaccine toxoid (+) hib vaccine conj (tet tox) (+) pertussis vaccine acellular 5-component (+) polio vaccine inact 3v (mrc 5) (+) tetanus vaccine toxoid (PENTACEL) (02-AUG-2011, 30-SEP-2011, 02-DEC-2011 and 31-AUG-2012), influenza vaccine (02-DEC-2011, 06-JAN-2012 and 03-DEC-2012), purified protein derivative (PPD) (29-MAY-2012), varicella vaccine (manufacturer unknown) (29-MAY-2012 and 08-JUN-2016), measles, mumps and rubella (MMR) vaccine (manufacturer unknown) (31-AUG-2012 and 08-JUN-2016), hepatitis A vaccine (manufacturer unknown) (03-DEC-2012 and 16-MAY-2013), diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (DTAP) vaccine (01-JUN-2015), injectable polio vaccine (01-JUN-2015), diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP) (28-JUN-2021) and diphtheria vaccine toxoid, hib vaccine conj (tet tox), pertussis vaccine acellular 5-component, polio vaccine inact 3v (mrc 5), tetanus vaccine toxoid (MENACTRA) (28-JUN-2022). The patient did not have illness at time of vaccination. There was no concomitant medication or other vaccines within 4 weeks prior to the vaccination date. The patient's pertinent medical history and drug reactions or allergies were not provided.  On 28-JUN-2022, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (strength, route of administration, exact dose, lot number and expiration date were not provided) for prophylaxis. On 27-JUN-2023, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (lot # W011455, expiration date: 11-DEC-2024; strength, route of administration and exact dose were not provided) at left arm for prophylaxis at private doctor's office/hospital by the reporting physician.   It was reported that the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (lot # W011455) was improper stored (product storage error). The vaccine was stored in clinical practice. According to manufacturer, the vaccine under temperature excursion vaccine was not viable. Alarm believed to be due to sensory issues. Temperatures was monitored with back up logger. The temperature was in range, and new data logger now was in use. The vaccines/waste was being returned in progress. No adverse effects. No prescription drug treatment was required for the experience. The event was reported to health department and manufacturer previously.  This is one of several reports from the same reporter. This is one of two reports for the same patient. ; Sender's Comments:  US-009507513-2306USA013096: US-009507513-2307USA010128: